A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia and Schizophrenia; Psychosis, sponsored by Karuna Therapeutics. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-12.
Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 2nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Karuna Therapeutics, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Karuna Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
21 studies in Schizophrenia by Bristol-Myers Squibb: 8 open now, 9 under way, 4 of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2020, is one of 13 in phase 3, and was the 3rd registered.
Bristol-Myers Squibb’s Schizophrenia studies by the year they started, since 2016.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics in adult inpatients with a DSM-5 diagnosis of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is capable of providing .
Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.
Positive and Negative Syndrome Scale total score between 80 and 120, inclusive. Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo
Drug pages: Xanomeline · Trospium chloride
Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
Also known as: KarXT
Placebo Capsules twice a day (BID)
Also known as: PBO
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. It takes approximately 45 to 50 minutes to administer. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Time frame: Baseline and Week 5
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. For positive symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Time frame: Baseline and Week 5
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5
The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. For negative symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Time frame: Baseline and Week 5
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score
The Marder Factor Negative Score is derived from the Positive and Negative Syndrome Scale (PANSS) and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Time frame: Baseline and Week 5
Change From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5
The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.
Time frame: Baseline and Week 5
Percentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 5
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 5.
Time frame: Baseline and Week 5
The study was conducted in 21 study centers in the United States.
| Milestone | KarXT | Placebo |
|---|---|---|
| Started | 126 | 126 |
| Completed | 94 | 100 |
| Not completed | 32 | 26 |
| Withdrew: Adverse event | 10 | 6 |
| Withdrew: Withdrawal by subject | 13 | 12 |
| Withdrew: Other | 9 | 8 |
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. It takes approximately 45 to 50 minutes to administer. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
| score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 | -21.2 ± 1.652 | -11.6 ± 1.600 |
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. For positive symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
| score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5 | -6.8 ± 0.526 | -3.9 ± 0.512 |
The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. For negative symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
| score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5 | -3.4 ± 0.479 | -1.6 ± 0.466 |
The Marder Factor Negative Score is derived from the Positive and Negative Syndrome Scale (PANSS) and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
| score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score | -4.2 ± 0.530 | -2.0 ± 0.517 |
The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.
| score on a scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5 | -1.2 ± 0.103 | -0.7 ± 0.099 |
The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 5.
| Participants | KarXT | Placebo |
|---|---|---|
| Percentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 5 | 51 | 28 |
Collected over From the start of study drug administration up to Week 5.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| KarXT | 0/126 (0%) | 2/126 (1.6%) | 95/126 (75.4%) |
| Placebo | 0/125 (0%) | 2/125 (1.6%) | 73/125 (58.4%) |
| Event | KarXT | Placebo |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 2/126 | 0/125 |
| AppendicitisInfections and infestations | 0/126 | 1/125 |
| SchizophreniaPsychiatric disorders | 0/126 | 1/125 |
| Event | KarXT | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 27/126 | 13/125 |
| DyspepsiaGastrointestinal disorders | 24/126 | 10/125 |
| NauseaGastrointestinal disorders | 24/126 | 7/125 |
| VomitingGastrointestinal disorders | 18/126 | 1/125 |
| HeadacheNervous system disorders | 17/126 | 15/125 |
| HypertensionVascular disorders | 12/126 | 1/125 |
| DizzinessNervous system disorders | 11/126 | 4/125 |
| AgitationPsychiatric disorders | 2/126 | 8/125 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 8/126 | 0/125 |
| Abdominal discomfortGastrointestinal disorders | 7/126 | 4/125 |
The Intent-to-Treat (ITT) population included all participants who were randomized to the study. Participants were analyzed according to randomized treatment.
| Age, Continuous(years) | KarXT | Placebo | Total |
|---|---|---|---|
| Mean | 45.6 ± 10.42 | 46.2 ± 10.78 | 45.9 ± 10.58 |
| Sex: Female, Male(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Female | 31 | 31 | 62 |
| Male | 95 | 95 | 190 |
| Ethnicity (NIH/OMB)(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 11 | 25 |
| Not Hispanic or Latino | 111 | 114 | 225 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Black or African American | 97 | 92 | 189 |
| White | 26 | 31 | 57 |
| Asian | 2 | 1 | 3 |
| Other | 1 | 2 | 3 |
| Region of Enrollment(participants) | KarXT | Placebo | Total |
|---|---|---|---|
| United States | 126 | 126 | 252 |
| Baseline PANSS Total Score(units on a scale) | KarXT | Placebo | Total |
|---|---|---|---|
| Mean | 98.3 ± 8.93 | 97.9 ± 9.71 | 98.1 ± 9.31 |
| Baseline PANSS Positive Score(units on a scale) | KarXT | Placebo | Total |
|---|---|---|---|
| Mean | 26.8 ± 3.74 | 26.7 ± 3.97 | 26.7 ± 3.85 |
| Baseline PANSS Negative Score(units on a scale) | KarXT | Placebo | Total |
|---|---|---|---|
| Mean | 22.9 ± 4.00 | 22.9 ± 3.82 | 22.9 ± 3.90 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in May 2022, 17 months.
Results were first posted in Dec 2023, 1 year 6 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 17 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium chloride